Apeloa Pharmaceutical Co.,Ltd

XSEC:000739 Stock Report

Market Cap: CN¥18.6b

Apeloa PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Apeloa PharmaceuticalLtd has been growing earnings at an average annual rate of 12.2%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 12.1% per year. Apeloa PharmaceuticalLtd's return on equity is 16.3%, and it has net margins of 8.8%.

Key information

12.2%

Earnings growth rate

12.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate12.1%
Return on equity16.3%
Net Margin8.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Apeloa PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:000739 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2412,2641,0741,101608
30 Jun 2411,9481,0791,143588
31 Mar 2411,5871,0601,135576
31 Dec 2311,4741,0551,127625
30 Sep 2311,4941,1831,034612
30 Jun 2311,5141,1531,005602
31 Mar 2311,5291,0761,048593
01 Jan 2310,545989998533
30 Sep 2210,094851970530
30 Jun 229,651839965523
31 Mar 229,077890906491
01 Jan 228,943956925446
30 Sep 218,468949973399
30 Jun 218,165941964369
31 Mar 218,146879986362
31 Dec 207,880817967350
30 Sep 207,6067521,074356
30 Jun 207,6537021,169383
31 Mar 207,2365981,241373
31 Dec 197,2115531,293360
30 Sep 197,1225291,332344
30 Jun 196,8554651,328299
31 Mar 196,6054141,324273
31 Dec 186,3763711,279270
30 Sep 186,2463671,198279
30 Jun 185,8823131,015392
31 Mar 185,6742751,000328
31 Dec 175,5522571,000259
30 Sep 175,313253986182
30 Jun 175,3122791,0880
31 Mar 175,1122741,0310
31 Dec 164,7722639770
30 Sep 164,4762019140
30 Jun 164,3491909100
31 Mar 164,2841988770
31 Dec 154,3382088610
30 Sep 154,1952318230
30 Jun 154,2192367680
31 Mar 154,2812417430
31 Dec 144,2333227190
30 Sep 144,1123136970
30 Jun 144,1003056710
31 Mar 143,9912746410
31 Dec 133,8551676080

Quality Earnings: 000739 has high quality earnings.

Growing Profit Margin: 000739's current net profit margins (8.8%) are lower than last year (10.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000739's earnings have grown by 12.2% per year over the past 5 years.

Accelerating Growth: 000739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 000739 had negative earnings growth (-9.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).

Return on Equity

High ROE: 000739's Return on Equity (16.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 15:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Apeloa Pharmaceutical Co.,Ltd is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Wanhua WuChina International Capital Corporation Limited
Shanshan LiChina Merchants Securities Co. Ltd.